FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012938217> ?p ?o ?g. }

• W2012938217 endingPage "e60089" @default.
• W2012938217 startingPage "e60089" @default.
• W2012938217 abstract "Chronic kidney disease (CKD) patients present elevated advanced glycation end products (AGEs) blood levels. AGEs promote inflammation through binding to their receptor (RAGE), located on the membrane of mesangial cells, endothelial cells and macrophages. Several genetic polymorphisms influence RAGE transcription, expression and activity, including the substitution of a thymine with an adenine (T/A) in the position -374 of the gene promoter of RAGE. Our study investigates the role of -374 T/A RAGE polymorphism in CKD progression in subjects affected by nephrocardiovascular disease.174 patients (119 males (68.4%) mean age 67.2±0.88 years; 55 females (31.6%): mean age 65.4±1.50 years) affected by mild to moderate nephrocardiovascular CKD were studied. Each subject was prospectively followed for 84 months, every 6-9 months. The primary endpoint of the study was a rise of serum creatinine concentrations above 50% of basal values or end stage renal disease.Carriers of the A/A and T/A genotype presented higher plasma levels of interleukin 6 (A/A 29.5±15.83; T/A 30.0±7.89, vs T/T 12.3±5.04 p = 0.01 for both) and Macrophages chemoattractant protein 1 (A/A 347.1±39.87; T/A 411.8±48.41, vs T/T 293.5±36.20, p = 0.04 for both) than T/T subjects. Carriers of the A allele presented a faster CKD progression than wild type patients (Log-Rank test: Chi square = 6.84, p = 0,03). Cox regression showed that -374 T/A RAGE polymorphism (p = 0.037), albuminuria (p = 0.01) and LDL cholesterol (p = 0.038) were directly associated with CKD progression. HDL cholesterol (p = 0.022) and BMI (p = 0.04) were inversely related to it. No relationship was found between circulating RAGE and renal function decline.-374 T/A RAGE polymorphism could be associated with CKD progression and inflammation. Further studies should confirm this finding and address whether inhibiting RAGE downstream signalling would be beneficial for CKD progression." @default.
• W2012938217 created "2016-06-24" @default.
• W2012938217 creator A5011125929 @default.
• W2012938217 creator A5029493814 @default.
• W2012938217 creator A5030398223 @default.
• W2012938217 creator A5030558259 @default.
• W2012938217 creator A5036863154 @default.
• W2012938217 creator A5057407225 @default.
• W2012938217 creator A5073608018 @default.
• W2012938217 creator A5077169554 @default.
• W2012938217 creator A5087573238 @default.
• W2012938217 creator A5091523473 @default.
• W2012938217 date "2013-04-04" @default.
• W2012938217 modified "2023-10-14" @default.
• W2012938217 title "-374 T/A RAGE Polymorphism Is Associated with Chronic Kidney Disease Progression in Subjects Affected by Nephrocardiovascular Disease" @default.
• W2012938217 cites W1964566884 @default.
• W2012938217 cites W1975932722 @default.
• W2012938217 cites W1976708244 @default.
• W2012938217 cites W1978657102 @default.
• W2012938217 cites W1985236743 @default.
• W2012938217 cites W1996976658 @default.
• W2012938217 cites W2017038002 @default.
• W2012938217 cites W2018939673 @default.
• W2012938217 cites W2039184577 @default.
• W2012938217 cites W2042293234 @default.
• W2012938217 cites W2056248104 @default.
• W2012938217 cites W2061810671 @default.
• W2012938217 cites W2062273929 @default.
• W2012938217 cites W2064115952 @default.
• W2012938217 cites W2065279621 @default.
• W2012938217 cites W2065764145 @default.
• W2012938217 cites W2068793587 @default.
• W2012938217 cites W2071125778 @default.
• W2012938217 cites W2073713671 @default.
• W2012938217 cites W2082322722 @default.
• W2012938217 cites W2085563576 @default.
• W2012938217 cites W2087511197 @default.
• W2012938217 cites W2088270621 @default.
• W2012938217 cites W2088639163 @default.
• W2012938217 cites W2092974802 @default.
• W2012938217 cites W2093059833 @default.
• W2012938217 cites W2093800517 @default.
• W2012938217 cites W2103093482 @default.
• W2012938217 cites W2106277117 @default.
• W2012938217 cites W2109863092 @default.
• W2012938217 cites W2112552231 @default.
• W2012938217 cites W2118046722 @default.
• W2012938217 cites W2124272802 @default.
• W2012938217 cites W2126728583 @default.
• W2012938217 cites W2127620487 @default.
• W2012938217 cites W2128013292 @default.
• W2012938217 cites W2130278873 @default.
• W2012938217 cites W2134120087 @default.
• W2012938217 cites W2136128927 @default.
• W2012938217 cites W2141088576 @default.
• W2012938217 cites W2143324145 @default.
• W2012938217 cites W2157645770 @default.
• W2012938217 cites W2163011148 @default.
• W2012938217 cites W2163194813 @default.
• W2012938217 cites W2163215334 @default.
• W2012938217 cites W2165325650 @default.
• W2012938217 cites W2404028691 @default.
• W2012938217 doi "https://doi.org/10.1371/journal.pone.0060089" @default.
• W2012938217 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3617170" @default.
• W2012938217 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23593165" @default.
• W2012938217 hasPublicationYear "2013" @default.
• W2012938217 type Work @default.
• W2012938217 sameAs 2012938217 @default.
• W2012938217 citedByCount "12" @default.
• W2012938217 countsByYear W20129382172013 @default.
• W2012938217 countsByYear W20129382172014 @default.
• W2012938217 countsByYear W20129382172015 @default.
• W2012938217 countsByYear W20129382172016 @default.
• W2012938217 countsByYear W20129382172017 @default.
• W2012938217 countsByYear W20129382172020 @default.
• W2012938217 countsByYear W20129382172022 @default.
• W2012938217 crossrefType "journal-article" @default.
• W2012938217 hasAuthorship W2012938217A5011125929 @default.
• W2012938217 hasAuthorship W2012938217A5029493814 @default.
• W2012938217 hasAuthorship W2012938217A5030398223 @default.
• W2012938217 hasAuthorship W2012938217A5030558259 @default.
• W2012938217 hasAuthorship W2012938217A5036863154 @default.
• W2012938217 hasAuthorship W2012938217A5057407225 @default.
• W2012938217 hasAuthorship W2012938217A5073608018 @default.
• W2012938217 hasAuthorship W2012938217A5077169554 @default.
• W2012938217 hasAuthorship W2012938217A5087573238 @default.
• W2012938217 hasAuthorship W2012938217A5091523473 @default.
• W2012938217 hasBestOaLocation W20129382171 @default.
• W2012938217 hasConcept C104317684 @default.
• W2012938217 hasConcept C126322002 @default.
• W2012938217 hasConcept C134018914 @default.
• W2012938217 hasConcept C135763542 @default.
• W2012938217 hasConcept C169760540 @default.
• W2012938217 hasConcept C180754005 @default.
• W2012938217 hasConcept C203014093 @default.
• W2012938217 hasConcept C2778653478 @default.
• W2012938217 hasConcept C2778857457 @default.
• W2012938217 hasConcept C2780306776 @default.

• next